StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
30
Publishing Date
2023 - 11 - 02
1
2023 - 07 - 05
1
2023 - 06 - 22
1
2022 - 12 - 15
1
2022 - 10 - 03
1
2022 - 09 - 20
1
2022 - 08 - 22
1
2022 - 03 - 23
1
2022 - 01 - 18
1
2022 - 01 - 11
1
2022 - 01 - 04
3
2022 - 01 - 03
1
2021 - 12 - 14
1
2021 - 12 - 06
2
2021 - 11 - 29
1
2021 - 11 - 15
1
2021 - 11 - 09
1
2021 - 10 - 04
1
2021 - 08 - 25
1
2021 - 04 - 22
1
2021 - 03 - 16
1
2021 - 03 - 03
1
2021 - 02 - 24
1
2021 - 01 - 11
1
2020 - 12 - 17
2
2020 - 12 - 15
1
Sector
Commercial services
1
Finance
2
Health technology
19
Manufacturing
2
Miscellaneous
1
N/a
1
Professional, scientific, and technical services
1
Tags
Acquisition
48
Biotech-beach
14
Business
33
Cancer
19
Ceo
72
Ces
65
Collaboration
17
Commercial
16
Companies
14
Conference
19
Corporation
28
Drug
23
Energy
53
Expansion
14
Fda
53
Financial
24
First
15
Global
29
Group
38
Growth
39
Health
17
International
17
Leo
18
Lithium
15
Liver
17
Management
26
Market
19
Meeting
28
Milestone
23
N/a
1641
Nasdaq
14
Offering
60
Partnership
22
People
17
Pharm-country
19
Pharmaceuticals
16
Phase 1
21
Phase 2
30
Phase 3
14
Platform
18
Pre-clinical
14
Preclinical
15
Program
38
Report
17
Research
55
Results
58
Services
15
Solutions
20
Study
48
Success
324
System
31
Technology
39
Test
45
Therapeutics
28
Therapy
15
Treatment
41
Trial
86
Trials
15
Update
20
Vaccine
17
Entities
180 life sciences corp.
1
Addex therapeutics ltd
1
Advaxis, inc.
1
Amgen inc.
2
Atai life sciences n.v.
1
Ayala pharmaceuticals, inc.
1
Betterlife pharma inc.
1
Bristol-myers squibb company
1
Celyad sa
1
Entera bio ltd.
2
Evolus, inc.
1
Gh research plc
1
Intertek group plc
1
Johnson & johnson
1
Lexicon pharmaceuticals, inc.
1
Longeveron llc - class a
2
Mind medicine inc (sub voting)
1
Moderna, inc.
1
Nascent biotech inc.
1
Novo nordisk a/s
1
Ocuphire pharma inc.
1
Pds biotechnology corporation
1
Pieris pharmaceuticals, inc.
1
Pliant therapeutics, inc.
1
Rafael holdings, inc.
2
Redhill biopharma ltd.
1
Scynexis, inc.
1
Swk holdings corporation
1
Ultragenyx pharmaceutical inc.
1
Vyne therapeutics inc.
2
Zentek ltd.
1
Symbols
ADXN
1
ADXS
1
AMGN
2
ATAI
1
ATNF
1
AYLA
1
BETRF
1
BMY
1
CYAD
1
ENTX
2
EOLS
1
GHRS
1
IKTSF
1
IKTSY
1
JNJ
1
LGVN
2
LXRX
1
MNMD
1
MRNA
1
NBIO
1
NVO
1
OCUP
1
PDSB
1
PIRS
1
PLRX
1
RARE
1
RDHL
1
RFL
2
SCYX
1
SWKH
1
VYNE
2
ZTEK
1
Exchanges
Nasdaq
27
Nyse
5
Crawled Date
2023 - 11 - 02
1
2023 - 07 - 05
1
2023 - 06 - 22
1
2022 - 12 - 15
1
2022 - 10 - 03
1
2022 - 09 - 20
1
2022 - 08 - 22
1
2022 - 03 - 23
1
2022 - 01 - 18
1
2022 - 01 - 11
1
2022 - 01 - 04
3
2022 - 01 - 03
1
2021 - 12 - 14
1
2021 - 12 - 06
2
2021 - 11 - 29
1
2021 - 11 - 15
1
2021 - 11 - 09
1
2021 - 10 - 04
1
2021 - 08 - 25
1
2021 - 04 - 22
1
2021 - 03 - 16
1
2021 - 03 - 03
1
2021 - 02 - 24
1
2021 - 01 - 11
1
2020 - 12 - 17
2
2020 - 12 - 15
1
Crawled Time
09:00
1
12:00
3
12:30
2
13:00
2
13:01
1
13:20
1
13:30
2
14:00
7
14:01
2
14:15
1
15:00
4
18:00
1
20:00
1
21:01
1
23:00
1
Source
www.biospace.com
19
www.globenewswire.com
11
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
success
tags :
Phase 2
save search
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy
Published:
2023-11-02
(Crawled : 12:00)
- globenewswire.com
OCUP
|
$1.76
1.15%
74K
|
Health Technology
|
-39.37%
|
O:
5.23%
H:
2.65%
C:
-8.94%
apx3330
fda
pharma
meeting
diabetic
phase 2
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
Published:
2023-07-05
(Crawled : 12:00)
- globenewswire.com
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-25.1%
|
O:
-0.19%
H:
1.07%
C:
0.65%
ADXS
|
$0.601
12.48%
4.9K
|
Health Technology
|
-40.5%
|
O:
1.24%
H:
0.0%
C:
-7.09%
al102
fda
tumors
treatment
pharmaceuticals
meeting
phase 2
Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®
Published:
2023-06-22
(Crawled : 13:00)
- biospace.com/
EOLS
|
$11.64
-3.4%
-3.52%
270K
|
Health Technology
|
47.49%
|
O:
-0.12%
H:
0.37%
C:
-2.08%
jeuveau
study
phase 2
Zentek Announces Successful Phase 2 Results of HVAC Testing
Published:
2022-12-15
(Crawled : 13:20)
- biospace.com/
ZTEK
|
$1.14
1.33%
13K
|
Professional, Scientific, and T...
|
-34.1%
|
O:
2.89%
H:
0.0%
C:
-6.74%
IKTSY
|
$59.99
-12.21%
1.9K
|
Professional, Scientific, and T...
|
18.08%
|
O:
-1.86%
H:
0.0%
C:
-0.96%
results
phase 2
PDS Biotech Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS0101 in Combination With KEYTRUDA®
Published:
2022-10-03
(Crawled : 14:00)
- biospace.com/
PDSB
|
$2.715
-3.04%
530K
|
Health Technology
|
-5.72%
|
O:
2.02%
H:
10.56%
C:
8.25%
pds0101
keytruda
fda
meeting
biotech
trial
phase 2
Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy
Published:
2022-09-20
(Crawled : 18:00)
- biospace.com/
LXRX
|
$1.65
-2.66%
3.4M
|
Health Technology
|
-31.38%
|
O:
0.4%
H:
4.03%
C:
2.02%
lx9211
pharmaceuticals
study
diabetic
phase 2
Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes
Published:
2022-08-22
(Crawled : 12:00)
- globenewswire.com
NVO
|
$124.29
0.68%
2.1M
|
Health Technology
|
18.08%
|
O:
3.78%
H:
0.49%
C:
-0.88%
trial
diabetes
phase 2
Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint
Published:
2022-03-23
(Crawled : 12:30)
- biospace.com/
MRNA
S
|
$102.82
-0.94%
1.1M
|
Health Technology
|
-44.41%
|
O:
-1.1%
H:
0.59%
C:
-3.21%
covid-19
children
vaccine
phase 2
Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
Published:
2022-01-18
(Crawled : 15:00)
- biospace.com/
RFL
4
|
$1.78
-1.11%
6.1K
|
Finance
|
-63.78%
|
O:
0.4%
H:
0.0%
C:
-8.42%
cpi-613
613
phase 2
als
ongoing
trial
gemcitabine
cancer
enroll
Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial
Published:
2022-01-11
(Crawled : 13:30)
- biospace.com/
NBIO
J
|
$0.0955
15.32%
75K
|
|
59.43%
|
O:
0.17%
H:
0.0%
C:
0.0%
phase 1
trial
phase 2
phase 3
cancer
train
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA
Published:
2022-01-04
(Crawled : 23:00)
- biospace.com/
ENTX
|
$2.14
-6.55%
-7.01%
210K
|
Health Technology
|
-29.1%
|
O:
8.57%
H:
0.0%
C:
-10.17%
AMGN
|
$264.07
-0.59%
-0.59%
2.2M
|
Health Technology
|
17.6%
|
O:
-0.41%
H:
0.0%
C:
0.0%
eb613
fda
phase 2
613
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC
Published:
2022-01-04
(Crawled : 20:00)
- biospace.com/
MNMD
|
$9.65
-2.33%
590K
|
n/a
|
550.0%
|
O:
-1.32%
H:
1.33%
C:
-1.33%
trial
phase 1
phase 2
phase 3
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
Published:
2022-01-04
(Crawled : 14:00)
- globenewswire.com
ENTX
|
$2.14
-6.55%
-7.01%
210K
|
Health Technology
|
-29.1%
|
O:
8.57%
H:
0.0%
C:
-10.17%
AMGN
|
$264.07
-0.59%
-0.59%
2.2M
|
Health Technology
|
17.6%
|
O:
-0.41%
H:
0.0%
C:
0.0%
eb613
fda
phase 2
bone
613
spine
phase 3
Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402
Published:
2022-01-03
(Crawled : 12:30)
- biospace.com/
PIRS
|
$0.157
-4.27%
470K
|
Health Technology
|
-95.66%
|
O:
1.59%
H:
3.52%
C:
1.82%
prs-060
phase 2
als
trial
milestone
phase 2b
atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia
Published:
2021-12-14
(Crawled : 13:00)
- biospace.com/
ATAI
|
$1.98
-7.91%
-8.59%
1.5M
|
Manufacturing
|
-80.51%
|
O:
-2.67%
H:
0.0%
C:
0.0%
rl-007
phase 2
schizophrenia
air
trial
life science
biomarkers
phase 2b
GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression
Published:
2021-12-06
(Crawled : 14:00)
- biospace.com/
GHRS
|
$11.02
0.27%
0.27%
78K
|
Manufacturing
|
-42.94%
|
O:
0.05%
H:
29.33%
C:
21.8%
treatment
phase 2
research
trial
phase 1
depression
180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results
Published:
2021-12-06
(Crawled : 13:30)
- globenewswire.com
ATNF
|
$1.91
29.05%
22.51%
310K
|
|
-60.95%
|
O:
-8.71%
H:
0.0%
C:
0.0%
phase 2
phase 2b
trial
trial results
ford
results
life science
BetterLife Successfully Completes Phase 1 and Initiates Phase 2 Clinical Trials with Interferon Alpha-2b in COVID-19 Patients in Chile
Published:
2021-11-29
(Crawled : 15:00)
- biospace.com/
BETRF
|
$0.0717
-3.71%
5.2K
|
Health Technology
|
-68.92%
|
O:
-2.17%
H:
5.94%
C:
-1.2%
phase 2
trials
trial
covid
clinical trials
phase 1
Addex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149
Published:
2021-11-15
(Crawled : 09:00)
- biospace.com/
JNJ
|
$144.11
-0.24%
6.4M
|
Health Technology
|
-13.64%
|
O:
-1.36%
H:
0.0%
C:
0.0%
ADXN
|
$22.8
0.89%
0.88%
16K
|
Health Technology
|
-85.38%
|
O:
2.85%
H:
1.14%
C:
1.14%
phase 1
phase 2
xin
phase 3
SCYNEXIS Announces Successful Completion of Phase 1 Trial Evaluating Intravenous (IV) Formulation of Ibrexafungerp
Published:
2021-11-09
(Crawled : 14:00)
- globenewswire.com
SCYX
|
$1.42
0.71%
130K
|
Health Technology
|
-75.31%
|
O:
0.61%
H:
0.0%
C:
0.0%
phase 1
trial
phase 2
phase 3
← Previous
1
2
Next →
Gainers vs Losers
55%
45%
Top 10 Gainers
INVO
|
$2.78
265.79%
200M
|
Health Technology
SINT
|
$0.0366
59.83%
460M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
$6.73
47.91%
32.39%
13M
|
GRTX
|
$0.237
39.41%
13M
|
Health Technology
TCON
|
$2.33
36.26%
26.61%
1.9M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
800K
|
VNDA
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
BCAN
|
$1.13
28.86%
22.4%
8.2M
|
Construction
Your saved searches
Save your searches and get alerts when important news are released.